EU PAL-COPD: Evaluation of the ICLEAR-EU intervention to integrate palliative care in the treatment of people with advanced COPD and their family caregivers

EU PAL-COPD：对 ICLEAR-EU 干预措施的评估，将姑息治疗纳入晚期 COPD 患者及其家庭护理人员的治疗中

• 批准号: 10109731
• 金额: $ 117.53万
• 依托单位: LANCASTER UNIVERSITY
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10109731
• 关键词: EU; PAL; COPD; Evaluation; ICLEAR

Chronic Obstructive Pulmonary Disease (COPD) is a devastating life-limiting lung disease with a high personal and societal burden. Worldwide, COPD is the third leading cause of death. The symptom burden of people with COPD is as severe and burdensome as the symptom burden of people with lung COPD. While palliative care in many countries is available for people with lung COPD, palliative care and good end-of-life care for people with COPD are not well integrated into their treatment by respiratory hospital teams in Europe. The EU PAL-COPD project is a multidisciplinary, interprofessional, international and intersectoral project aiming at evaluating the clinical and cost-effectiveness of the ICLEAR-EU intervention for people with advanced COPD in different healthcare systems in Europe. ICLEAR-EU is a person-centred and family-centred non-pharmacological service intervention in which respiratory teams in the hospital collaborate with interdisciplinary palliative care teams and with primary care to promote shared decision-making and advance care planning, improve symptom treatment and comfort care, and prevent re-hospitalization after an exacerbation. ICLEAR-EU is based on an existing intervention developed and pilot tested in the UK. In EU PAL-COPD, the effectiveness of ICLEAR-EU will be assessed with a stepped wedge cluster RCT in 1,224 people with advanced COPD in 18 hospitals across six European countries. It is hence the first large-scale international trial on systematic integration of palliative care in respiratory care for people with advanced COPD. Cost-effectiveness, robust mixed methods subgroup analyses and in-depth process and implementation evaluations are also included. EU PAL-COPD will improve the well-being and empowerment of people with COPD and their families and advance the state of the art by providing an innovative service model to the complex palliative and end-of-life care needs. User and stakeholder involvement is crucial throughout the project

慢性阻塞性肺疾病（COPD）是一种毁灭性的限制生命的肺部疾病，具有很高的个人和社会负担。在世界范围内，COPD是第三大死亡原因。COPD患者的症状负担与肺部COPD患者的症状负担一样严重和沉重。虽然许多国家的慢性阻塞性肺病患者可获得姑息治疗，但欧洲的呼吸系统医院团队并未将慢性阻塞性肺病患者的姑息治疗和良好的临终护理很好地纳入其治疗。欧盟PAL-COPD项目是一个多学科、跨专业、国际和跨部门的项目，旨在评估ICLEAR-EU对欧洲不同医疗保健系统中晚期COPD患者进行干预的临床和成本效益。ICLEAR-EU是一个以人为中心和以家庭为中心的非药物服务干预措施，其中医院的呼吸团队与跨学科姑息治疗团队和初级保健合作，以促进共同决策和推进护理规划，改善症状治疗和舒适护理，并防止病情加重后再次住院。ICLEAR-EU是基于在联合王国制定和试点测试的现有干预措施。在EU PAL-COPD中，将在6个欧洲国家的18家医院的1，224例晚期COPD患者中采用阶梯楔形集RCT评估ICLEAR-EU的有效性。因此，这是第一个在晚期COPD患者呼吸护理中系统整合姑息治疗的大规模国际试验。还包括成本效益、稳健的混合方法、分组分析以及深入的过程和执行评价。EU PAL-COPD将改善COPD患者及其家人的福祉和赋权，并通过提供创新的服务模式来满足复杂的姑息治疗和临终护理需求，从而推动最新技术水平。用户和利益相关者的参与在整个项目中至关重要